Filing Details
- Accession Number:
- 0001104659-15-029743
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-04-23 16:48:38
- Reporting Period:
- 2015-04-21
- Filing Date:
- 2015-04-23
- Accepted Time:
- 2015-04-23 16:48:38
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1267813 | Marinus Pharmaceuticals Inc | MRNS | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1614780 | M Gail Farfel | C/O Marinus Pharma, Inc. 3 Radnor Corp. Center 100 Matsonford Rd, Ste 304 Radnor PA 19087 | Chief Clinical Dev & Reg Offic | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2015-04-21 | 30,000 | $1.04 | 30,000 | No | 4 | M | Direct | |
Common Stock | Disposition | 2015-04-21 | 30,000 | $9.48 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock option (right to buy) | Disposition | 2015-04-21 | 30,000 | $0.00 | 30,000 | $1.04 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
8,462 | 2020-04-01 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 15, 2015. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.34 to $9.53, inclusive. The reporting person undertakes to provide to Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.
- 25% vested on 4/1/11; remaining shares vested in equal installments at the end of each of the 36 months after 4/1/11.